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Background and Purpose Long-term changes in post-stroke depression (PSD), post-stroke emo-
tional incontinence (PSEI), and post-stroke anger (PSA) have rarely been studied.
Methods This is a sub-study of EMOTION, a randomized, placebo-controlled trial, that examined 
the efficacy of escitalopram on PSD, PSEI, and PSA in patients with stroke. We interviewed pa-
tients at the long-term period (LTP) using predefined questionnaires: Montgomery-Åsberg depres-
sion rating scale (MADRS) for PSD, modified Kim’s criteria for PSEI, and Spielberger trait anger 
scale for PSA. Additionally, the ENRICHD Social Support Instrument (ESSI) for the social support 
state and the modified Rankin Scale (mRS) were measured. We investigated the changes in and 
factors behind PSD, PSEI, and PSA at LTP.
Results A total of 222 patients were included, and the median follow-up duration was 59.5 
months (interquartile range, 50 to 70). Compared to the data at 6 months post-stroke, the preva-
lence of PSEI (11.7% at 6 months, 6.3% at LTP; P=0.05) and mean anger score (21.62, 16.24; 
P<0.01) decreased, while the prevalence of PSD (35.6%, 44.6%; P=0.03) and mean MADRS (6.16, 
8.67; P<0.01) increased at LTP. ESSI was associated with PSD and PSA, but not with PSEI. The ef-
fect of the baseline National Institutes of Health Stroke Scale score on PSD decreased over time. 
The effect of low social support on PSD was greater than that of mRS at LTP. 
Conclusions The prevalence and degree of PSD significantly increased, while those of PSEI and PSA 
decreased at LTP. PSD in this stage appeared to be more closely associated with a lack of social 
support than patients' physical disabilities.
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Introduction
Patients with stroke often develop mood and emotional distur-
bances, including post-stroke depression (PSD), post-stroke 
emotional incontinence (PSEI), and post-stroke anger (PSA).1-3 
A recent meta-analysis showed that about one-third of pa-
tients have PSD at any time within 5 years after stroke.4 The 
prevalence of PSEI and PSA in the early phase has been report-
ed to be 6% to 34% and 15% to 35%, respectively.3
The pathogenesis of these mood and emotional disturbances 
is similar, but not identical. For PSEI and PSA, serotonergic dys-
function caused by stroke lesions appears to play an important 
role.3 Although this could also account for the development of 
PSD, the pathophysiology of PSD appears more complex be-
cause of the strong involvement of familial/psychosocial fac-
tors.5 Thus, the pathophysiology of PSD may differ according to 
the time point after the stroke.5,6
The prevalence of and associated factors for these distur-
bances in the long-term period (LTP) have been rarely stud-
ied.3,4 The aim of this study was to investigate the prevalence 
of and associated factors for PSD, PSEI, and PSA at LTP, using 
follow-up data from the Efficacy of Early Administration of Es-
citalopram on Depressive and Emotional Symptoms and Neu-
rologic Dysfunction After Stroke (EMOTION) trial, a dou-
ble-blind, placebo-controlled, randomized study.
Methods
Study design and participants
This is a sub-study of the EMOTION trial (ClinicalTrials.gov 
NCT01278498) previously performed in 17 university hospitals 
in South Korea. Briefly, we enrolled patients who (1) were aged 
≥20 years; (2) had an acute stroke within 21 days before ran-
domization; and (3) had a modified Rankin Scale (mRS) score 
of ≥2 at the screening stage. We excluded patients who had (1) 
been diagnosed with psychiatric diseases before the index 
stroke; (2) severe dementia or aphasia; and (3) strong suicidal 
thoughts. Finally, 478 patients were enrolled and randomly ad-
ministered either escitalopram (10 mg/day) or placebo for 3 
months. The outcome variables were assessed at baseline, 3, 
and 6 months post-stroke.7
In this sub-study, we measured the long-term outcomes of 
PSD, PSEI, and PSA. EMOTION investigators were invited to join 
this sub-study. This study was approved by the Institutional 
Review Boards (IRBs) of the hospitals. Informed consent was 
obtained from all participants.
Assessments
Data obtained from EMOTION trial
Information on demographics, risk factors, and clinical and 
outcome variables was obtained from the EMOTION trial. De-
pressive symptoms were measured using the Montgomery-Ås-
berg depression rating scale (MADRS),8,9 and the presence of 
PSD was defined by MADRS ≥8.10,11 Emotional incontinence 
was assessed using modified Kim’s criteria7 and dichotomized 
as “present” or “not present.” Anger score was measured using 
the modified Spielberger trait anger-Kim’s scale7 (Supplemen-
tary Table 1). The range of the anger score was 10 to 40 points 
(higher scores indicating more severe symptoms), and it was 
analyzed as a continuous variable in this study. We did not 
consider cut-off anger score for the definition of PSA. Stroke 
symptoms and functional deficits were evaluated using the 
National Institutes of Health Stroke Scale (NIHSS)12 and mRS,13 
respectively.
We aimed to examine the natural course of PSD, PSEI, and 
PSA. As escitalopram was administered for 3 months in the 
EMOTION trial and the duration was considered sufficient to 
wash out the pharmacological effect,14 we used data at 6 
months post-stroke in addition to the data obtained at LTP.
Long-term follow-up assessment
We investigated PSD, PSEI, PSA, and mRS at LTP. Additionally, 
social support was measured using the enhancing recovery in 
coronary heart disease (ENRICHD) Social Support Instrument 
(ESSI). This instrument measures structural, instrumental, and 
emotional support15 (higher scores indicating better social sup-
port). We defined “low social support” as reported previously:16 
a total score of five items (1, 2, 3, 5, and 6) in ESSI of <19, and 
a score of <3 on at least any two items. We also asked the pa-
tients about the use of antidepressants and/or psychiatric clinic 
visits to manage their emotional problems.
Statistical analysis
Baseline variables are presented as number with percentage (%), 
mean±standard deviation, or median with interquartile range, as 
appropriate. For comparison of any two independent groups, we 
used chi-square test, Student’s t-test, or Mann-Whitney U test. 
We conducted a simple regression test using baseline character-
istics as independent variables, and PSD, PSEI, and anger score at 
6 months post-stroke and LTP as outcomes. We then performed 
multiple logistic regression test adjusting for important factors 
(P<0.1) from the result of the simple regression test. The correla-
tions between MADRS at LTP and ESSI and those between anger 
score at LTP and ESSI were analyzed using Spearman’s rank cor-
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relation coefficient. The effect of mRS and ESSI on PSD at LTP 
was also analyzed using an adjusted logistic regression test. All 
statistical calculations were performed using IBM SPSS Statistics 
for Windows version 24.0 (IBM Co., Armonk, NY, USA) or R ver-
sion 3.6.0 (R Foundation for Statistical Computing, Vienna, 
Austria). Statistical significance was set at α=0.05.
Results 
Seven of 17 hospitals that had previously participated in the 
EMOTION trial were included in this sub-study. The other cen-
ters could not perform this study because of the investigators 
being transferred to other hospitals, loss of interest, or practi-
cal difficulties in performing the study (e.g., IRBs allowing di-
rect but not telephone interviews). The seven hospitals had 
previously enrolled 356 patients in the EMOTION trial, 222 of 
whom consented to participate. The major reasons for 
non-participation were the inability to establish contact (46 
patients, 34.3%), patients’ reluctance to participate (31 pa-
tients, 23.1%), missing data (26 patients, 19.4%), and patients 
Table 1. Baseline characteristics and clinical variables of participants and non-participants
Characteristic Participants (n=222) Non-participants (n=134) P
Age (yr) 63.0 (53.0–70.0) 70.5 (60.0–76.0) <0.01
Female sex 86 (38.7) 53 (39.6) 0.97
Hypertension 167 (75.2) 108 (80.6) 0.30
Diabetes 93 (41.9) 54 (40.3) 0.85
Hyperlipidemia 112 (50.5) 80 (59.7) 0.11
Coronary artery disease 35 (15.8) 16 (11.9) 0.40
Smoking 116 (52.3) 69 (51.5) 0.98
Family history of stroke 58 (26.1) 35 (26.1) 1.00
Lesion location 0.14
Anterior circulation 139 (62.6) 83 (61.9)
Posterior circulation 77 (34.7) 51 (38.1)
Both 6 (2.7) 0 (0)
Lesion side 0.06
Right 99 (44.6) 72 (53.7)
Left 107 (48.2) 59 (44.0)
Both 16 (7.2) 3 (2.2)
MADRS 9.3±8.0 11.8±9.1 0.01
PSD 113 (50.9) 78 (58.2) 0.22
PSEI 19 (8.6) 6 (4.5) 0.21
Anger score 22.9±5.5 23.9±5.3 0.09
NIHSS 4.0 (3.0–7.0) 5.0 (3.0–7.0) 0.04
mRS 4.0 (3.0–5.0) 5.0 (4.0–5.0) 0.16
Non-use of escitalopram 110 (49.5) 68 (50.7) 0.91
Values are presented as median (interquartile range), number (%), or mean±standard deviation. 
MADRS, Montgomery-Åsberg depression rating scale; PSD, post-stroke depression; PSEI, post-stroke emotional incontinence; NIHSS, National Institutes of 
Health Stroke Scale; mRS, modified Rankin Scale.
Cohort of EMOTION trial
478 Patients  
in 17 university hospitals
Eligible patients
356 Patients  
in 7 university hospitals
Investigators' 
  - Moving to other hospitals 
  - Refusal to join this sub-study
Difficulty in obtaining IRB
122 Patients 
in 10 university hospitals
134 Patients were excluded 
  - 46 Loss of contact
  - 31 Refusal
  - 26 Missing follow-up data
  - 22 Death
  - 2 Severe dementia
  - 7 Miscellaneous
222 Patients joined 
in this sub-study
Figure 1. Study profile. EMOTION, Efficacy of Early Administration of Esci-
talopram on Depressive and Emotional Symptoms and Neurologic Dysfunc-
tion After Stroke; IRB, Institutional Review Board.
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passing away (22 patients, 16.4%) (Figure 1).
Fifty-one of 222 patients were interviewed face-to-face at 
the outpatient clinic, and the others were interviewed via tele-
phone by a trained investigator. The investigators obtained 
written consent (or verbal consent on the telephone) and in-
terviewed them using a pre-established questionnaire. If possi-
ble, relatives or caregivers were also interviewed to confirm the 
patient’s responses. All interviews were conducted between 
May 2017 and May 2018.
The duration from the index stroke to LTP ranged from 35 to 
83 months (60 [range, 50 to 70]). All participants lived in their 
homes, except for four who were in the sanitarium. Nine of 
222 patients (4.1%) experienced recurrent stroke. Twenty-nine 
of 222 (13.0%) were taking antidepressants, and 28 (12.6%) 
were regularly visiting psychiatric clinics. Of 99 patients with 
PSD at LTP, only 20 (20.2%) were being treated. A total of 78 
patients (35.1%) had low social support. There were no signifi-
cant differences in baseline characteristics between partici-
pants and non-participants, except that non-participants were 
older and had higher MADRS and NIHSS scores (Table 1).
Compared to the mRS 6 months post-stroke (3.0 [2.0 to 
4.0]), the median mRS at LTP (1.50 [0.75 to 3.00], P<0.01) de-
creased (Figure 2A), whereas the prevalence of PSD (35.6% to 
44.6%, P=0.03) and mean MADRS (6.2 to 8.7, P<0.01) in-
creased (Figure 2B). The prevalence of PSEI (11.7% to 6.3%, 
P=0.05) and mean anger score at LTP (21.6 to 16.2, P<0.01) 
decreased (Figure 2C and D).
We studied the relationships between demographic and clin-
ical factors, and the use of escitalopram, and PSD, PSEI, and 
anger score at 6 months and at LTP in a simple regression 
analysis (Table 2). Variables showing significant effects 
(P<0.05) were baseline PSEI and NIHSS for PSEI at 6 months; 
left side lesion, baseline PSEI, and NIHSS for PSEI at LTP; and 
female sex, baseline anger score for PSA at both 6 months and 
LTP. Female sex, baseline MADRS, PSD, and NIHSS were signifi-
cant factors for PSD at 6 months, while age, hyperlipidemia, 
baseline MADRS, PSD, and NIHSS were significantly associated 
with PSD at LTP.
Multiple logistic regression analysis after adjustment for im-
































































































Figure 2. (A) Median modified Rankin Scale (mRS) with interquartile range. (B) Prevalence of post-stroke depression (PSD) and mean Montgomery-Åsberg de-
pression rating scale (MADRS) with 95% confidence interval (CI). (C) Prevalence of post-stroke emotional incontinence. Follow-up time is shown in month. (D) 
Mean anger score with 95% CI. LTP, long-term period.
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Table 2. Simple regression test using PSD, PSEI, and anger score as outcomes
Variable
PSD PSEI Anger score
OR (95% CI) P OR (95% CI) P Beta (95% CI) P
Age
6 mo 1.00 (0.98 to 1.03) 0.78 0.99 (0.95 to 1.02) 0.44 –0.13 (–0.26 to 0.00) 0.05
LTP 1.03 (1.01 to 1.05) 0.02 1.00 (0.95 to 1.04) 0.90 –0.06 (–0.19 to 0.07) 0.36
Female sex
6 mo 2.16 (1.23 to 3.80) 0.01 1.41 (0.62 to 3.22) 0.41 –0.16 (–0.29 to –0.03) 0.02
LTP 1.67 (0.97 to 2.87) 0.07 1.63 (0.55 to 4.83) 0.38 –0.15 (–0.28 to –0.02) 0.03
Hypertension
6 mo 1.19 (0.63 to 2.28) 0.59 0.58 (0.24 to 1.40) 0.23 0.07 (–0.07 to 0.20) 0.32
LTP 1.59 (0.85 to 2.98) 0.15 0.82 (0.25 to 2.72) 0.74 0.13 (0.00 to 0.26) 0.05
Diabetes
6 mo 1.74 (1.00 to 3.04) 0.05 1.02 (0.45 to 2.33) 0.96 0.02 (–0.11 to 0.16) 0.72
LTP 1.51 (0.88 to 2.59) 0.13 0.36 (0.10 to 1.32) 0.12 –0.03 (–0.16 to 0.10) 0.63
Hyperlipidemia
6 mo 1.39 (0.80 to 2.41) 0.25 0.69 (0.30 to 1.58) 0.38 –0.05 (–0.18 to 0.08) 0.46
LTP 2.45 (1.42 to 4.21) <0.01 1.33 (0.45 to 3.98) 0.61 0.11 (–0.02 to 0.25) 0.09
Smoking
6 mo 0.66 (0.38 to 1.15) 0.14 1.08 (0.47 to 2.44) 0.86 0.09 (–0.04 to 0.23) 0.16
LTP 0.76 (0.45 to 1.29) 0.31 0.91 (0.31 to 2.68) 0.86 0.13 (–0.01 to 0.26) 0.06
Lesion location
Anterior circulation Reference Reference Reference
Posterior circulation
6 mo 0.81 (0.45 to 1.43) 0.46 0.87 (0.37 to 2.06) 0.76 0.01 (–0.12 to 0.14) 0.87
LTP 0.92 (0.53 to 1.60) 0.78 0.44 (0.12 to 1.61) 0.21 –0.02 (–0.15 to 0.11) 0.78
Lesion side
Right side Reference Reference Reference
Left side
6 mo 0.74 (0.43 to 1.29) 0.29 0.93 (0.41 to 2.12) 0.86 –0.03 (–0.16 to 0.10) 0.63
LTP 0.65 (0.38 to 1.11) 0.11 0.20 (0.05 to 0.74) 0.02 –0.11 (–0.25 to 0.02) 0.09
Baseline MADRS
6 mo 1.18 (1.12 to 1.24) <0.01 0.99 (0.94 to 1.05) 0.81 0.02 (–0.11 to 0.16) 0.72
LTP 1.08 (1.04 to 1.12) <0.01 0.99 (0.92 to 1.06) 0.72 0.07 (–0.06 to 0.21) 0.27
Baseline PSD
6 mo 9.19 (4.68 to 18.03) <0.01 1.14 (0.50 to 2.60) 0.75 0.03 (–0.10 to 0.17) 0.62
LTP 3.50 (2.01 to 6.12) <0.01 0.71 (0.24 to 2.11) 0.54 0.05 (–0.08 to 0.18) 0.45
Baseline PSEI
6 mo 2.16 (0.84 to 5.56) 0.11 5.65 (1.99 to 16.06) <0.01 –0.03 (–0.16 to 0.11) 0.69
LTP 1.80 (0.69 to 4.66) 0.23 5.15 (1.44 to 18.38) 0.01 0.06 (–0.07 to 0.19) 0.40
Baseline anger score
6 mo 1.01 (0.96 to 1.07) 0.59 0.98 (0.91 to 1.05) 0.55 0.59 (0.49 to 0.70) <0.01
LTP 1.02 (0.97 to 1.07) 0.41 0.93 (0.84 to 1.02) 0.13 0.23 (0.11 to 0.36) <0.01
Baseline NIHSS
6 mo 1.21 (1.09 to 1.34) <0.01 1.24 (1.09 to 1.42) <0.01 –0.03 (–0.16 to 0.11) 0.69
LTP 1.14 (1.04 to 1.26) 0.01 1.24 (1.05 to 1.46) 0.01 0.11 (–0.02 to 0.25) 0.09
Non-use of escitalopram
6 mo 1.35 (0.78 to 2.35) 0.28 1.22 (0.54 to 2.76) 0.64 0.00 (–0.13 to 0.14) 0.95
LTP 1.00 (0.59 to 1.69) 0.99 1.39 (0.46 to 4.13) 0.56 –0.07 (–0.20 to 0.06) 0.28
Logistic regression test for binary variables (PSD, PSEI) and linear regression test for continuous variable (anger score). Beta refers to the standardized beta co-
efficient of the linear regression test. The PSD, PSEI, and anger score at 6 months post-stroke were used to identify significant factors. 
PSD, post-stroke depression; PSEI, post-stroke emotional incontinence; OR, odds ratio; CI, confidence interval; LTP, long-term period; MADRS, Montgomery-
Åsberg depression rating scale; NIHSS, National Institutes of Health Stroke Scale. 
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significantly (P<0.05) associated: baseline PSD and NIHSS for 
PSD at 6 months, hyperlipidemia and baseline PSD for PSD at 
LTP, baseline PSEI and NIHSS for PSEI at 6 months, left-side le-
sion and baseline PSEI at LTP, age and baseline anger score for 
PSA at 6 months, and baseline anger score and NIHSS for PSA 
at LTP (Table 3). There was no autocorrelation or multicol-
linearity in the multiple regression test. 
Figure 3 shows the relationships of ESSI with MADRS and 
with anger score at LTP. The correlation test showed a signifi-
cant negative relationship between MADRS and ESSI (ρ=–
0.39, P<0.01) and between anger score and ESSI (ρ=–0.28, 
P<0.01).
Table 4 shows the effect of low social support and mRS at 
LTP on PSD, PSEI, and anger scores at LTP. In the simple regres-
sion test, the effect of low social support and mRS on PSD was 
statistically significant. The significance remained in the multi-
ple regression test after adjustment for age, sex, baseline PSD, 
baseline NIHSS, regular psychiatric clinic visits at LTP, antide-
pressant use at LTP, and recurrent stroke at LTP. However, the 
effect of low social support on PSD at LTP was greater than that 
of mRS. There was no interaction between low social support 
and mRS at LTP (P=0.53). Neither mRS nor low social support 
Table 3. Multiple regression test using PSD, PSEI, and anger score at 6 months post-stroke and LTP as outcomes
Variable
6 Months post-stroke LTP
OR or beta (95% CI) P OR or beta (95% CI) P 
PSD*
Age (yr) 0.97 (0.94 to 1.00) 0.07 1.02 (0.99 to 1.04) 0.20
Female sex 2.01 (1.01 to 3.98) 0.05 1.23 (0.66 to 2.27) 0.52
Diabetes 1.45 (0.75 to 2.82) 0.27 1.07 (0.59 to 1.94) 0.82
Hyperlipidemia 1.07 (0.55 to 2.07) 0.84 2.22 (1.23 to 3.98) 0.01
Baseline PSD 8.66 (4.23 to 17.73) <0.01 2.81 (1.57 to 5.04) <0.01
Baseline NIHSS 1.17 (1.04 to 1.32) 0.01 1.10 (0.99 to 1.23) 0.07
PSEI*
Lesion side, left 1.16 (0.48 to 2.79) 0.74 0.22 (0.06 to 0.85) 0.03
Baseline PSEI 4.93 (1.68 to 14.51) <0.01 4.84 (1.25 to 18.78) 0.02
Baseline NIHSS 1.24 (1.07 to 1.43) <0.01 1.19 (0.99 to 1.42) 0.06
Anger score†
Age (yr) –0.14 (–0.25 to –0.02) 0.02 –0.08 (–0.22 to 0.05) 0.24
Female sex 0.05 (–0.11 to 0.21) 0.54 –0.09 (–0.27 to 0.10) 0.38
Hypertension 0.00 (–0.11 to 0.11) 0.97 0.10 (–0.04 to 0.23) 0.16
Hyperlipidemia –0.01 (–0.12 to 0.10) 0.85 0.11 (–0.02 to 0.24) 0.11
Smoking –0.01 (–0.16 to 0.15) 0.93 0.02 (–0.16 to 0.21) 0.80
Lesion side, left 0.01 (–0.10 to 0.12) 0.83 –0.09 (–0.22 to 0.04) 0.17
Baseline anger score 0.61 (0.49 to 0.72) <0.01 0.20 (0.07 to 0.34) <0.01
Baseline NIHSS 0.02 (–0.09 to 0.13) 0.76 0.14 (0.01 to 0.27) 0.04
Logistic regression test for binary variables (PSD, PSEI) and linear regression test for continuous variable (anger score). Beta refers to the standardized beta co-
efficient of the linear regression test. The PSD, PSEI, and anger score at 6 months post-stroke were used to identify significant factors. 
PSD, post-stroke depression; PSEI, post-stroke emotional incontinence; LTP, long-term period; OR, odds ratio; CI, confidence interval; NIHSS, National Insti-








0 10 20 30 40
ESSI at LTP
MADRS at LTP 
(rho=−0.39, P<0.01, R2=0.13)
Anger score at LTP 
(rho=−0.28, P<0.01, R2=0.07)
Figure 3. Correlation test results between Montgomery-Åsberg depression 
rating scale (MADRS) at long-term period (LTP) and enhancing recovery in 
coronary heart disease (ENRICHD) Social Support Instrument (ESSI), and 
between anger score at LTP and ESSI. 
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was significantly associated with PSEI at LTP. For PSA, the effect 
of low social support on the anger score at LTP was significant 
in the adjusted test. We additionally tested the relationship of 
ESSI or mRS with “PSD treatment” among patients with PSD at 
LTP. ESSI was positively associated with psychiatric clinic visits 
in the logistic regression test (odds ratio, 1.13; 95% confidence 
interval, 1.02 to 1.25; P=0.03), while mRS was not (P=0.11).
Discussion
To our knowledge, our study is the first to investigate the long-
term (average 5 years) changes in PSD, PSEI, and PSA. We 
found that the prevalence of PSD and mean MADRS score 
gradually increased over time. We had previously found that 
the MADRS scores at the early stage of stroke decreased along 
Table 4. Simple and adjusted regression test of low social support and mRS at LTP, using PSD, PSEI, and anger score at LTP as outcomes
Variable
Simple test Adjusted test
OR or beta (95% CI) P OR or beta (95% CI) P 
PSD at LTP*
Age (yr) 0.98 (0.95 to 1.01) 0.23
Female sex 1.53 (0.74 to 3.18) 0.25
Baseline PSD 3.12 (1.56 to 6.24) <0.01
Baseline NIHSS 0.90 (0.79 to 1.03) 0.13
Regular clinic visit 3.50 (1.11 to 11.03) 0.03
Antidepressant use 3.38 (1.02 to 11.18) 0.05
Recurrent stroke 0.46 (0.09 to 2.42) 0.36
mRS 2.12 (1.67 to 2.70) <0.01 2.16 (1.54 to 3.02) <0.01
Low social support 3.46 (1.94 to 6.16) <0.01 4.12 (1.97 to 8.66) <0.01
PSEI at LTP*
Age (yr) 0.98 (0.92 to 1.04) 0.47
Female sex 1.51 (0.43 to 5.25) 0.52
Baseline PSEI 3.94 (0.92 to 16.85) 0.06
Baseline NIHSS 1.12 (0.90 to 1.40) 0.32
MADRS at LTP 1.07 (0.99 to 1.15) 0.08
Regular clinic visit 0.31 (0.03 to 3.61) 0.35
Antidepressant use 1.68 (0.34 to 8.22) 0.52
Recurrent stroke 0.52 (0.04 to 7.74) 0.64
mRS 1.39 (0.95 to 2.04) 0.09 0.96 (0.50 to 1.84) 0.90
Low social support  3.63 (1.17 to 11.23) 0.03 2.01 (0.53 to 7.69) 0.31
Anger score at LTP†
Age (yr) –0.10 (–0.23 to 0.03) 0.14
Female sex –0.06 (–0.18 to 0.07) 0.38
Baseline anger score 0.22 (0.10 to 0.34) <0.01
Baseline NIHSS 0.06 (–0.07 to 0.18) 0.39
MADRS 0.45 (0.31 to 0.59) <0.01
Regular clinic visit 0.11 (–0.01 to 0.23) 0.07
Antidepressant use 0.04 (–0.08 to 0.17) 0.52
Recurrent stroke 0.04 (–0.07 to 0.16) 0.48
mRS 0.11 (–0.02 to 0.24) 0.10 –0.14 (–0.30 to 0.02) 0.09
Low social support 0.25 (0.12 to 0.38) <0.01 0.14 (0.02 to 0.26) 0.03
Logistic regression test for binary variables (PSD, PSEI) and linear regression test for continuous variable (anger score). Beta refers to the standardized beta co-
efficient of the linear regression test. 
mRS, modified Rankin Scale; LTP, long-term period; PSD, post-stroke depression; PSEI, post-stroke emotional incontinence; OR, odds ratio; CI, confidence in-
terval; NIHSS, National Institutes of Health Stroke Scale; MADRS, Montgomery-Åsberg de pression rating scale.
*OR; †Beta.
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with improvement in neurological deficits, probably due to 
psychological responses associated with improving neurologi-
cal deficits.7 Our results are not consistent with a previous lon-
gitudinal study from the South London Stroke Register (SLSR). 
In this study, the prevalence of PSD defined by depression sub-
scale score >7 in the Hospital Anxiety and Depression Scale 
was stationary over time: 33% (30% to 36%), 28% (25% to 
30%), and 31% (27% to 34%) at 3 months, 1 year, and 5 years 
after stroke, respectively.17 Direct comparisons should be made 
cautiously because our study and the SLSR study are method-
ologically different. We conducted direct or phone interviews, 
whereas a postal interview was used in the SLSR study. While 
222 of 356 patients (62.4%) were followed up at LTP in our 
study, only 585 out of 3,689 (15.9%) were followed up at 5 
years in the SLSR study. 
Nevertheless, the gradual increase in the degree and preva-
lence of PSD over time in our study needs to be discussed. Al-
though mRS scores were still independent factors associated 
with PSD at LTP (Table 4), they gradually decreased over time 
in our study (Figure 2). Thus, the increasing prevalence of PSD 
at LTP is unlikely to be attributed to worsening functional dis-
ability.18 We found that low social support was significantly as-
sociated with PSD at LTP. Although we did not investigate ESSI 
at earlier time points, the strong relationship between ESSI and 
MADRS at LTP (Figure 3) suggests that the lack of social sup-
port may be one of the reasons for the persistent or increasing 
prevalence of PSD. We also found that only approximately 20% 
of patients with PSD were under treatment. Although the 
treatment status was not described in the SLSR study, this fac-
tor may have contributed to the difference. In Korea, some de-
pressive patients do not visit psychiatric clinics because of the 
social stigma attached to psychiatric diseases.19 More elderly 
Koreans regard depression as a “personal weakness” or “normal 
aging” instead of a “disease” than Americans.20 It was reported 
that the use of antidepressants in Korea was one of the lowest 
among OECD countries.21 All these factors may have contribut-
ed to the prevalent PSD at LTP in our cohort.
We noted that aside from baseline PSD and NIHSS scores, 
hyperlipidemia was a factor associated with PSD at LTP (Table 
3). Although a study from Taiwan showed that patients with 
hyperlipidemia had a high risk of depression,22 a meta-analysis 
of the relationship between vascular risk factors and late-life 
depression did not show such an association.23 Further studies 
are required to confirm the relationship between PSD and hy-
perlipidemia. 
We found that the prevalence and severity of PSEI decreased 
from 6 months post-stroke to LTP (Figure 2). This result was 
consistent with a report that revealed that the prevalence of 
PSEI decreased from 21% at 6 months post-stroke to 11% at 
12 months post-stroke.24 Numerous studies have shown that 
PSEI is pathophysiologically closely associated with serotoner-
gic system dysfunction in the brain in stroke patients.1,25-28 
Thus, the decreasing prevalence of PSEI at LTP may be attribut-
ed to the recovery of the damaged serotonergic system in the 
brain over time. Unlike PSD, PSEI was not associated with ESSI 
in our study. The anger score also decreased from 6 months 
post-stroke to LTP (Figure 2). This may also be explained by the 
improved brain serotonergic system over time. However, unlike 
PSEI, the anger score was associated with low social support 
(Figure 3), although the relationship was not as strong as that 
with PSD. It has been shown that although PSA is closely asso-
ciated with brain serotonergic system dysfunction, it is also re-
lated to depression and frustration.3
This study has a few limitations. First, since only Korean pa-
tients were enrolled, it may be difficult to apply the results to 
other ethnicities. Second, as we examined social support only 
once at LTP, its impact on patients’ emotions at 6 months re-
mains unknown. Third, we could not categorize lesion location 
precisely because the number of patients with PSD, PSEI, and 
high anger score were small. Fourth, since LTP was not pre-de-
fined in this sub-study, the range of LTP was rather broad (35 
to 85 months). Finally, many patients did not participate in the 
study. Compared with participants, non-participants were older 
and had higher initial MADRS and NIHSS scores (Table 1). In 
our study, multiple regression analysis showed that baseline 
PSD, but not MADRS score, was associated with PSD at LTP, 
and the initial NIHSS score was associated with PSA at LTP. Al-
though it is difficult to precisely assess the possible impact of 
these differences on our results, the frequencies of post-stroke 
mood/emotional disturbances at LTP may have been underesti-
mated in our study. This is an inherent problem in the research 
on depression; individuals with depression are more cautious 
and hesitant about clinical trial participation than those with-
out.29 However, we do not think that this limitation greatly in-
fluenced our main findings, as our primary aim was to observe 
the long-term change in post-stroke emotional disorders rather 
than assess the exact prevalence of these symptoms in a cer-
tain period. 
Despite these limitations, our data showed that the preva-
lence and degree of PSEI and anger score decreased, whereas 
those of PSD increased at LTP in our cohort. Our results have 
several practical implications. Physicians may consider cessa-
tion of medications for PSEI at LTP but need to be aware of the 
increased prevalence of PSD. As PSD and PSA are associated 
with a lack of social support, strategies to improve social sup-
port may have to be developed to prevent and manage PSD 
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and PSA at LTP. 
Supplementary materials
Supplementary materials related to this article can be found 
online at https://doi.org/10.5853/jos.2020.04637.
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Supplementary Table 1. Criteria for post-stroke emotional incontinence and anger used in this study
Original definition Modified*
Kim’s criteria for post-stroke 
  emotional incontinence (PSEI)2
Patients and relatives were asked if the patient showed excessive or inappropriate 
  laughing, crying, or both, as compared with the premorbid state. 
PSEI was confirmed when both the patient and relatives agree that they occurred 
  on more than two occasions.
Inappropriateness indicates laughing or crying that occurs while talking, listening, 
   meeting people, or watching television, when the incident is not particularly 
amusing or sad to ordinary people.
Same as the original definition, 
   but relative’s confirmation was 
not required 
Spielberger trait anger-Kim’s scale 
  for post-stroke anger (PSA)
Assessment of PSA† was supported by application of the 10-item Spielberger 
  Trait Anger Scale. 
For each question, patients were asked to use a numerical scale (1, almost never; 2, 
   sometimes; 3, often; and 4, almost always) to best represent their pre-stroke and 
current (post-stroke) statuses, separately. An overall anger score was obtained by 
summation of individual scores. PSA was defined to be present when (1) the sum 
of the PSA score was higher than that of pre-stroke score; (2) the patient felt that 
he or she had developed PSA; and (3) at least one of the relatives who lived with 
the patient agreed on number 2.
Same as the original definition, 
   but relative’s confirmation was 
not required and the PSA was not 
compared with the pre-stroke 
score.
*Originals were modified for clinical trials. By omitting “relative's confirmation” we were able to include patients who lived alone and could more easily per-
form telephone or postal interview. We were also able to decrease the burden on investigators and patients in the trial; †The term “inability to control anger 
and aggression” was used in the original paper. 
